Adult Cancer Survivors of a hemato-oncological disease (ICD-10 C00–C97) C00-C97
Conditions
Interventions
Group 1: N = 500 participants in the intervention cohort (University Cancer Center Hamburg (UCC Hamburg), University Medical Center Hamburg-Eppendorf), who receive the following intervention as part o
Sponsors
Universitäres Cancer Center Hamburg, Universitätsklinikum Hamburg-Eppendorf
Eligibility
Sex/Gender
All
Age
18 Years to 65 Years
Inclusion criteria
Inclusion criteria: N = 500 participants in the intervention cohort (University Cancer Center Hamburg (UCC Hamburg), University Medical Center Hamburg-Eppendorf): - Diagnosis of a hemato-oncological disease (ICD-10 C00–C97) - First diagnosis in adulthood (= 18 years) - Completion of tumor therapy (exception: ongoing adjuvant hormone therapy) - Residency in the Hamburg metropolitan region and ability to present at least once at the UCC Hamburg for study enrollment - Eligible at any point of follow-up: immediately after completion of active tumor therapy, during tumor-specific follow-up (generally up to 5 years post-treatment), or during long-term follow-up (> 5 years post-treatment) N = 250 participants in the control cohort (University Medical Center Schleswig-Holstein (UKSH), Campus Kiel): - No Participation in a Survivorship-Program: usual care - Age 18–65 years at the time of study enrollment - Diagnosis of a hemato-oncological disease (ICD-10 C00–C97) - First diagnosis in adulthood (= 18 years) - Completion of tumor therapy (exception: ongoing adjuvant hormone therapy) - Eligible at any point of follow-up: immediately after completion of active tumor therapy, during tumor-specific follow-up (generally up to 5 years post-treatment), or during long-term follow-up (> 5 years post-treatment)
Exclusion criteria
Exclusion criteria: - Non-German-speaking individuals for whom completion of the questionnaires is not feasible - Presence of a psychiatric disorder (e.g., psychosis, dementia) that prevents completion of the questionnaires
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Health-Related Quality of Life (HRQoL), assessed by Short-Form-Health-Survey (SF-12) (Ware et al., 1996): - Mental HRQoL, assessed by Mental Component Score (MCS) of the SF-12 (Ware et al., 1996) - Physical HRQoL, assessed by Physical Component Score (PCS) of the SF-12 (Ware et al., 1996) | — |
Secondary
| Measure | Time frame |
|---|---|
| Assessed for the intervention and control cohort: Health-Related Quality of Life (HRQoL), assessed by Short-Form-Health-Survey (SF-12) (Ware et al., 1996) in comparison to control cohort: - Mental HRQoL (in comparison to control cohort), assessed by Mental Component Score (MCS) of the SF-12 (Ware et al., 1996) - Physical HRQoL (in comparison to control cohort), assessed by Physical Component Score (PCS) of the SF-12 (Ware et al., 1996) The following only assessed for the intervention cohort: - Self-Efficacy, assessed by Self-Efficacy Scale (SES6G) (Freund et al., 2013) - Health literacy, assessed by European Health Literacy Questionnaire Shortform (HLS-EU-Q16) (Sørensen et al., 2013) - Empowerment, assessed by Patient Enablement (PEN-13) (Siegel et al., 2019) - Supportive care needs, assessed by Short-Form Supportive Care Needs Survey Questionnaire (SCNS-SF34-G) (Lehmann et al., 2012) Somatic condition: - Global health status, assessed by EORTC Quality of Life Module “Survivorship“ (QLQ-SURV100) (Van Leeuwen et al., 2023), Scale “Global health status” - Fatigue, assessed by EORTC Quality of Life Module „Survivorship“ (QLQ-SURV100) (Van Leeuwen et al., 2023), Scale “Fatigue” - Physical Functioning/Polyneuropathy, assessed by EORTC Quality of Life Module “Survivorship“ (QLQ-SURV100) (Van Leeuwen et al., 2023), Scale “Symptom checklist” (Polyneuropathy), “Physical functioning”, “Pain” - Sexuality/Fertility, assessed by EORTC Quality of Life Module “Survivorship“ (QLQ-SURV100) (Van Leeuwen et al., 2023), Scale “Sexual functioning”, “Sexual pleasure”, “Sexual problems”, “Sexual problems female”, “Sexual problems when sexually active”, “Sexual problems male” and “Fertility” - Sleep, assessed by EORTC Quality of Life Module “Survivorship“ (QLQ-SURV100) (Van Leeuwen et al., 2023), Scale “Sleep Problems” Mental condition: - Distress, assessed by Distress Thermometer (Mehnert-Theuerkauf et al., 2006) - Depression and Anxiety, assessed by Patient | — |
Countries
Germany
Contacts
Public ContactMarianne Sinn
Universitäres Cancer Center Hamburg, Universitätsklinikum Hamburg-Eppendorf
Outcome results
None listed